This year saw notable progress in head and neck cancers, Huntington's disease, personalized genetic therapy, and heart ...

On a video call in early September, Sarah Tabrizi first saw the data that she and other researchers studying Huntington’s ...

They manage to slow down the progression of Huntington's disease using a gene therapy treatment called AMT 130.

Investor optimism has waned as final minutes from uniQure’s pre-BLA meeting with the FDA convey that data from the company’s Phase I/II studies of AMT-130 are “unlikely” to provide the primary ...

A charity representing people with Huntington’s disease has said it is “worried and saddened” by mistreatment findings at a ...

Juvenile Huntington’s disease is more aggressive than Huntington’s disease, reducing a child’s life expectancy at a far ...

UCL and uniQure report the first treatment to slow Huntington’s disease with gene therapy AMT-130. High-dose patients had 75% less progression over three years compared with standard care. uniQure ...

Dublin, Nov. 14, 2025 (GLOBE NEWSWIRE) -- The "Huntington's Disease Market - A Global and Regional Analysis: Focus on Drug Class and Region - Analysis and Forecast, 2025-2035" report has been added to ...

Novartis has discontinued two undisclosed programs under its current partership with Voyager, the biotech announced last month. Projects under the deal for spinal muscular atrophy and Huntington’s ...